This is consistent with the results of a metabolomic analysis of severe COVID-19 patients, which found that AnxA1 plays an important role in infection with severe acute respiratory syndrome coronavirus (SARS-CoV-2)—the causative agent of COVID-19—and is a potential therapeutic target [11]. This evidence concerns the gene ANXA1 and COVID-19.